These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 27116515)

  • 1. Recurrent Central Serous Chorioretinopathy Under Combined Vemurafenib and Cobimetinib Treatment.
    Kouros P; Gerding H
    Klin Monbl Augenheilkd; 2016 Apr; 233(4):488-9. PubMed ID: 27116515
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study.
    de la Cruz-Merino L; Di Guardo L; Grob JJ; Venosa A; Larkin J; McArthur GA; Ribas A; Ascierto PA; Evans JTR; Gomez-Escobar A; Barteselli G; Eng S; Hsu JJ; Uyei A; Dréno B
    J Transl Med; 2017 Jun; 15(1):146. PubMed ID: 28646893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.
    Larkin J; Ascierto PA; Dréno B; Atkinson V; Liszkay G; Maio M; Mandalà M; Demidov L; Stroyakovskiy D; Thomas L; de la Cruz-Merino L; Dutriaux C; Garbe C; Sovak MA; Chang I; Choong N; Hack SP; McArthur GA; Ribas A
    N Engl J Med; 2014 Nov; 371(20):1867-76. PubMed ID: 25265494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study.
    Dréno B; Ribas A; Larkin J; Ascierto PA; Hauschild A; Thomas L; Grob JJ; Koralek DO; Rooney I; Hsu JJ; McKenna EF; McArthur GA
    Ann Oncol; 2017 May; 28(5):1137-1144. PubMed ID: 28444112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene Expression Profiling in
    Wongchenko MJ; McArthur GA; Dréno B; Larkin J; Ascierto PA; Sosman J; Andries L; Kockx M; Hurst SD; Caro I; Rooney I; Hegde PS; Molinero L; Yue H; Chang I; Amler L; Yan Y; Ribas A
    Clin Cancer Res; 2017 Sep; 23(17):5238-5245. PubMed ID: 28536307
    [No Abstract]   [Full Text] [Related]  

  • 6. Posterior reversible encephalopathy syndrome due to combination of vemurafenib and cobimetinib for metastatic melanoma.
    Boukari F; Dugourd PM; Chassang M; Mondot L; Passeron T; Lacour JP; Montaudie H
    Pigment Cell Melanoma Res; 2017 Mar; 30(2):262-264. PubMed ID: 27885826
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma.
    Sanlorenzo M; Choudhry A; Vujic I; Posch C; Chong K; Johnston K; Meier M; Osella-Abate S; Quaglino P; Daud A; Algazi A; Rappersberger K; Ortiz-Urda S
    J Am Acad Dermatol; 2014 Dec; 71(6):1102-1109.e1. PubMed ID: 25440439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cobimetinib Plus Vemurafenib: A Review in BRAF (V600) Mutation-Positive Unresectable or Metastatic Melanoma.
    Keating GM
    Drugs; 2016 Apr; 76(5):605-15. PubMed ID: 26984388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The safety and efficacy of cobimetinib for the treatment of BRAF V600E or V600K melanoma.
    Amaral T; Nouri N; Garbe C
    Expert Rev Anticancer Ther; 2016 Jul; 16(7):705-15. PubMed ID: 27219630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Demyelinating polyradiculoneuropathy under combined BRAF/MEK inhibitors.
    Devic P; Amini-Adle M; Camdessanché JP; Dalle S
    Eur J Cancer; 2017 Jun; 78():103-104. PubMed ID: 28432982
    [No Abstract]   [Full Text] [Related]  

  • 11. Systemic inflammatory reaction syndrome during combined kinase inhibitor therapy following anti-PD-1 therapy for melanoma.
    Urosevic-Maiwald M; Mangana J; Dummer R
    Ann Oncol; 2017 Jul; 28(7):1673-1675. PubMed ID: 28459947
    [No Abstract]   [Full Text] [Related]  

  • 12. [Cobimetinib/vemurafenib-associated bilateral serous retinopathy: a case report].
    Kastl G
    Ophthalmologe; 2019 Aug; 116(8):785-788. PubMed ID: 30357465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined inhibition of BRAF and MEK in melanoma patients.
    Infante JR; Swanton C
    Lancet Oncol; 2014 Aug; 15(9):908-10. PubMed ID: 25037140
    [No Abstract]   [Full Text] [Related]  

  • 14. Vitiligo in 2 patients receiving vemurafenib for metastatic melanoma.
    Alonso-Castro L; Ríos-Buceta L; Vano-Galvan S; Moreno C; Soria-Rivas A; Jaén P
    J Am Acad Dermatol; 2013 Jul; 69(1):e28-9. PubMed ID: 23768302
    [No Abstract]   [Full Text] [Related]  

  • 15. Dermoscopic Evaluation of Melanocytic Nevi Changes With Combined Mitogen-Activated Protein Kinase Pathway Inhibitors Therapy for Melanoma.
    Perier-Muzet M; Boespflug A; Poulalhon N; Caramel J; Breton AL; Thomas L; Dalle S
    JAMA Dermatol; 2016 Oct; 152(10):1162-1164. PubMed ID: 27463731
    [No Abstract]   [Full Text] [Related]  

  • 16. The relative clinical efficacy of trametinib-dabrafenib and cobimetinib-vemurafenib in advanced melanoma: an indirect comparison.
    Galván-Banqueri M; Ubago-Pérez R; Molina-López T
    J Clin Pharm Ther; 2016 Jun; 41(3):285-9. PubMed ID: 27079278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug reaction with eosinophilia and systemic symptoms syndrome induced by combination of vemurafenib and cobimetinib in melanoma: A series of 11 cases.
    Brégeon B; Bernier C; Josselin N; Peuvrel L; Le Moigne M; Saint-Jean M; Quéreux G
    J Am Acad Dermatol; 2019 Feb; 80(2):558-562. PubMed ID: 30081108
    [No Abstract]   [Full Text] [Related]  

  • 18. Adjunction of a MEK inhibitor to Vemurafenib in the treatment of metastatic melanoma results in a 60% reduction of acute kidney injury.
    Teuma C; Pelletier S; Amini-Adl M; Perier-Muzet M; Maucort-Boulch D; Thomas L; Laville M; Fouque D; Dalle S
    Cancer Chemother Pharmacol; 2017 May; 79(5):1043-1049. PubMed ID: 28396940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vemurafenib-Induced Disseminated Intravascular Coagulation in Metastatic Melanoma.
    van den Brom RR; Mäkelburg AB; Schröder CP; de Vries EG; Hospers GA
    J Clin Oncol; 2015 Dec; 33(36):e133-4. PubMed ID: 24778390
    [No Abstract]   [Full Text] [Related]  

  • 20. Cobimetinib (Cotellic) for metastatic melanoma.
    Med Lett Drugs Ther; 2016 Mar; 58(1491):43-4. PubMed ID: 27027689
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.